Cartesian Therapeutics (FRA:1S70) EPS (Basic): €-5.05 (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1S70 Cartesian Therapeutics Inc FRA:1S70
27 GF Score
Price €6.60
GF Value €0.23
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Cartesian Therapeutics EPS (Basic)?

Cartesian Therapeutics FRA:1S70 +2.33% 27 EPS (Basic) is €-5.05 as of Mar. 2026. GuruFocus rates FRA:1S70 with a GF Score™ of 27/100 and a GF Value™ of €0.23 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Cartesian Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €-1.26. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €-5.05.

Cartesian Therapeutics's EPS (Diluted) for the three months ended in Mar. 2026 was €-1.26. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-5.06.

Cartesian Therapeutics's EPS without NRI for the three months ended in Mar. 2026 was €-0.85. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -2.44.

During the past 3 years, the average EPS without NRI Growth Rate was -59.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 21.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 34.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 12 years, Cartesian Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 72.90% per year. The lowest was -59.70% per year. And the median was 28.30% per year.

Cartesian Therapeutics  (FRA:1S70) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Cartesian Therapeutics EPS (Basic) Related Terms

Cartesian Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Cartesian Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cartesian Therapeutics EPS (Basic) Chart

Cartesian Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.84 6.80 -45.63 -4.28 -4.29

Cartesian Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.63 0.44 -1.18 -3.05 -1.26
FRA:1S70
27GF Score
Cartesian Therapeutics Inc FRA:1S70
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cartesian Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Cartesian Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-111.278-0)/25.973
=-4.28

Cartesian Therapeutics's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-33.892-0)/26.855
=-1.26

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-5.05 mean?
Cartesian Therapeutics (FRA:1S70) has a EPS (Basic) of €-5.05 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Cartesian Therapeutics and its competitors.
Is Cartesian Therapeutics' EPS (Basic) too high?
Cartesian Therapeutics' current EPS (Basic) is €-5.05. Overall, Cartesian Therapeutics has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cartesian Therapeutics' EPS (Basic) compare to LYEL and ALXO?
Cartesian Therapeutics' EPS (Basic) of €-5.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Cartesian Therapeutics and its competitors. Cartesian Therapeutics's current EPS (Basic) is €-5.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cartesian Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Cartesian Therapeutics (FRA:1S70) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.23, compared to a current price of €6.60 — trading 2769.6% above its estimated fair value. The current EPS (Basic) is €-5.05. Cartesian Therapeutics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Cartesian Therapeutics (FRA:1S70), the current EPS (Basic) is €-5.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cartesian Therapeutics (FRA:1S70) Overvalued in 2026?

Based on GuruFocus' analysis, Cartesian Therapeutics stock appears to be overvalued. The current stock price of €6.60 is trading 2769.6% above its estimated GF Value™ of €0.23. GuruFocus considers Cartesian Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:1S70:

  • EPS (Basic): €-5.05
  • GF Value™: €0.23 vs. price of €6.60 (2769.6% above fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the FRA:1S70 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cartesian Therapeutics Business Description

Other Exchanges RNAC:USA
Address 7495 New Horizon Way, Frederick, MD, USA, 21703
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
27GF Score

Get the complete analysis for FRA:1S70

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.60
Price
€0.23
GF Value